Abstract
The development of monoclonal antibodies targeting various receptors and ligands has been a significant advance in cancer therapy. These monoclonal antibodies are generally well tolerated. A subset of patients, however, experience infusion reactions with symptoms ranging from mild to life-threatening anaphylaxis. The underlying mechanisms of these reactions are not well characterized. In this review, current findings in clinical risk factor assessments and known mechanisms of these infusion reactions are discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 14-17 |
| Number of pages | 4 |
| Journal | Oncology |
| Volume | 23 |
| Issue number | 2 Suppl 1 |
| State | Published - Feb 2009 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research